Vivani Medical VANI Biopharm Division — Labor And Related Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vivani Medical in its filing.
Tagged under the XBRL concept us-gaap:LaborAndRelatedExpense.
The official record: Vivani Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vivani Medical's biopharm division — labor and related expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vivani Medical's biopharm division — labor and related expense?
- Vivani Medical (VANI) reported biopharm division — labor and related expense of $2.61M in Q1 2026.
- How has Vivani Medical's biopharm division — labor and related expense changed year-over-year?
- Vivani Medical's biopharm division — labor and related expense increased by 5.5% year-over-year, from $2.47M to $2.61M.
- What is the long-term trend for Vivani Medical's biopharm division — labor and related expense?
- Over 2 years (2023 to 2025), Vivani Medical's biopharm division — labor and related expense has grown at a 2.8% compound annual growth rate (CAGR), from $9.72M to $10.28M.
- What does biopharm division — labor and related expense mean?
- Captures the total compensation costs, including salaries, benefits, and stock-based compensation, for personnel dedicated to the biopharmaceutical segment. This represents the human capital investment required to drive research and development initiatives. Tracking this expense helps evaluate the segment's commitment to maintaining the specialized talent necessary for complex drug delivery technology.